• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 11, 2014

View Archived Issues

Galapagos shares drop as Glaxosmithkline axes JAK1 program after drug-drug interaction

Shares in Galapagos NV were down 9 percent Friday on news that Glaxosmithkline plc terminated development of its selective Janus kinase 1 (JAK1) inhibitor GSK2586184 in several chronic inflammatory conditions after a statin-associated drug-drug interaction became apparent in a phase I study. Read More

Medivation wows market with Xtandi earnings, future game plan

U.S. sales of Xtandi (enzalutamide) jumped 74 percent in the second quarter over the same period a year earlier, to $143.7 million, Medivation Inc. reported after Thursday's market close, and the company's second quarter revenue from its collaboration with partner Astellas Pharma Inc. soared 111 percent over the same period in 2013, to $148.1 million. Read More

Tolero series B garnering $14M for anti CDK effort; AML phase III next year

With a multi-cyclin-dependent kinase (CDK) small-molecule inhibitor working its way toward phase III trials next year in acute myeloid leukemia (AML), Tolero Pharmaceuticals Inc. raised $14.2 million in series B money that will also help advance the Salt Lake City-based firm's significant preclinical pipeline. Read More

3SBio inks licensing deal with Korea's Dinona for leukemia candidate

HONG KONG – Shenyang, China-based 3SBio Inc. has entered an exclusive licensing agreement with Korean biotech Dinona Inc. for 3SBio to develop, manufacture and market leukotuximab in Greater China to offer better treatment to Chinese leukemia patients and reinforce its blood-related disorders pipeline. Read More

Best way to look at inflammation data is in dispute

The debate continues about how good mouse models of inflammation are, with a paper published this week in the Proceedings of the National Academy of Sciences (PNAS) taking issue with a 2013 report that there is next to no correlation between mouse and human changes in gene expression in several inflammatory disorders. Read More

Yabao, Le Sun are collaborating to develop oncology candidate

SHANGHAI – Yabao Pharmaceutical Co. Inc. has agreed to co-develop with Le Sun Pharmaceutical Ltd. their leading PLK/PI3K dual inhibitor LS-008. On its hunt to find candidates with global potential, Chinese pharma Yabao will team up with the local biotech to accelerate development for the preclinical oncology candidate. Read More

Ebola is declared an international emergency by WHO

LONDON – The World Health Organization (WHO) on Monday is convening a meeting of medical and scientific experts and ethicists to consider the use of non-approved drugs as emergency treatments for Ebola, after declaring the outbreak of the viral infection in West Africa an international emergency. Read More

Other news to note

Alcobra Ltd., of Tel Aviv, Israel, released new imaging data on brain activity associated with metadoxine extended-release (MDX) treatment. Read More

Stock movers

Read More

In the clinic

Biospecifics Technologies Corp., of Lynbrook, N.Y., said it has injected the first patient in its placebo-controlled phase II trial of Xiaflex (collagenase clostridium histolyticum or CCH) to treat lipoma. Read More

Earnings

Spectrum Pharmaceuticals Inc., of Henderson, Nev., said product sales were $46.9 million in the second quarter of 2014, compared to $32.2 million in the same period last year. Read More

Appointments and advancements

Blueprint Medicines Corp., of Cambridge, Mass., named Jeffrey Albers CEO. Read More

Financings

Jazz Pharmaceuticals plc, of Dublin, said Jazz Investments I Ltd., its wholly owned subsidiary, priced its previously announced offering of $500 million aggregate principal amount of exchangeable senior notes due 2021. Read More

Bench Press: BioWorld looks at translational medicine

Under certain circumstances, apparently, stress can be good for inflammatory disorders. The current dogma is that stress exacerbates inflammation, but researchers from the University of California at San Francisco have shown that psychological stress improved three separate inflammatory skin conditions in mice – contact dermatitis, allergic contact dermatitis and eczema. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • 3D heart in chest

    At CRVBC 2025: Aging is circulating in your blood

    BioWorld Science
    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins,...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe